On 22 February 2017, Mark Zylka described how candidate environmental risk factors for autism can be identified rationally, by pinpointing chemicals that interfere with the same molecular pathways that are affected in individuals with autism.
On 1 February 2017, Arnold Kriegstein described recent advances in our understanding of the unique features of human cortical development and discussed insights into the origins of neurodevelopmental disorders.
On 25 January 2017, Jeremy Veenstra-VanderWeele outlined critical challenges to translating genomic, cellular, and animal model research into new treatments for autism spectrum disorder.
Associate Professor of Neurology, Harvard Medical School
On 2 November 2016, Beth Stevens discussed recent work that implicates brain immune cells, called microglia, in sculpting of synaptic connections during development and their relevance to autism, schizophrenia and other brain disorders.
Professor in Neurology, Harvard Medical School
On 5 October 2016, Mustafa Sahin presented an update on translational research in Tuberous Sclerosis Complex.
On 7 September 2016, Ruth O'Hara discussed the field’s current understanding of sleep in autism spectrum disorder.